Pharmaceutical plant in Novosyolki technopark

The plant is certified according to the GMP standard, located on a site of 19 hectares and includes 13 thousand m2 of production premises. The plant produces drugs designed to treat diseases in the field of cardiology and neurology, as well as diseases of the endocrine system. The design capacity of the plant as of December 2020 is almost 2 billion tablets per year.

Investments in the plant amounted to 65 million US dollars. The plant gives Yaroslavl about 200 jobs for highly qualified personnel ^[1]

History

2021: Completion of sale of R-Pharm plant

On February 19, 2021, the R-Farm group of companies and Teva announced the successful completion of the acquisition of R-Farm from the Teva pharmaceutical plant located on the territory of the Yaroslavl Industrial Park (Novosyolki). The purchase of a complex certified according to the GMP standard and producing drugs for the treatment of socially significant diseases will allow R-Pharm to adapt production capacities to the needs of the healthcare system.

As of February 2021, the site, which includes 13 thousand m2 of production premises, is producing drugs that are intended primarily for the treatment of diseases in the field of cardiology and neurology, as well as diseases of the endocrine system. The design capacity of the plant is about 2 billion tablets per year. In the future, modernization will allow the production of drugs for a wider range of therapeutic areas.

The terms of the sale of the plant imply a five-year industrial partnership between R-Farm and Teva to ensure uninterrupted access of patients to the drugs that are produced at the Teva enterprise.

"Thanks to the deal with Teva, the R-Farm group of companies is growing not only with modern equipment and advanced production capacities, but also, equally importantly, with a wide range of competencies and deep expertise, which will allow us to solve strategic tasks for the further development of production in Yaroslavl," said R-Farm CEO Vasily Ignatiev.

"We are pleased to cooperate with R-Farm and successfully complete the transaction on mutually beneficial terms for the parties. The sale of the enterprise, which demonstrates good capacity utilization and stable financial indicators, is designed to optimize operating costs and further increase the efficiency of Teva Pharmaceutical Industries Ltd, "commented Eric Roche, senior vice president, head of the Teva Russia, Eurasia, Turkey, the Middle East and Africa cluster, CEO of Teva Russia.

2020: Sale of the plant to the R-Pharm group of companies

On December 2, 2020, it became known that Teva is selling a pharmaceutical enterprise located on the territory of the Yaroslavl Industrial Park (Novosyolki), to the R-Farm group of companies. The amount of the transaction was not disclosed.

Teva sells its pharmaceutical plant in Yaroslavl to the R-Farm group. Source photo: gmpnews.ru

Teva's decision to sell the plant in Yaroslavl corresponds to the strategy of the company's global network, which was designed to optimize overall competitiveness and best adapt production capacities to market and patient demand.

After obtaining the necessary permits from antitrust authorities, the plant in Yaroslavl will transfer from Teva to the R-Farm group of companies. The terms of the sale of the site include a five-year agreement, during which R-Pharm will act as a production partner of Teva to ensure patients' access to Teva drugs, which are manufactured at the Yaroslavl enterprise as of December 2020. In addition, in accordance with the terms of the agreement, R-Farm will retain jobs for plant employees to ensure site stability and a smooth transition.

The plant's facilities will continue to produce medicines for the treatment of socially significant diseases in the field of cardiology, neurology and the endocrine system, which are in demand on the Russian market.

We are pleased to announce another milestone in the history of R-Farm and look forward to the plant in Yaroslavl and its employees joining our team. The Teva complex is a pharmaceutical company, and such a transaction is well consistent with our strategic plans to increase production volumes. The group of companies continues to expand the product portfolio, replenish it with both its own developments and localized drugs of our partners. Increasing production will make these drugs more accessible to Russian patients, commented by Vasily Ignatiev, General Director of R-Farm.

Despite the sale of the production plant, Teva's strategic goals in Russia remain unchanged. Our company seeks to improve the lives of Russian patients, and the Russian market is one of the priority regions for our business, commented Eric Roche, Senior Vice President, Cluster Head Teva Russia, Eurasia , Turkey, Middle East & Africa, CEO Teva Russia.

Notes